Braysen: Evidence-Based Insights for Expecting Parents on This Emerging Prenatal Supplement Brand

What Is Braysen—and Why It’s Gaining Attention Among Birth Professionals

Braysen is a U.S.-based prenatal supplement brand founded in 2022 by a team including an OB-GYN, a registered dietitian specializing in maternal nutrition, and a pharmaceutical formulation scientist. Unlike many legacy prenatal brands, Braysen was developed using evidence from the 2021 NIH Consensus Development Conference on Folic Acid and Neural Tube Defect Prevention, which emphasized optimal dosing of bioavailable folate, choline, and vitamin D for early pregnancy support. Its flagship product—Braysen Complete Prenatal—contains 800 mcg of L-5-methyltetrahydrofolate (the active form of folate), 550 mg of choline bitartrate, 2,000 IU of vitamin D3, and 27 mg of elemental iron as ferrous bisglycinate—all dosed within Institute of Medicine (IOM) upper intake levels and aligned with American College of Obstetricians and Gynecologists (ACOG) 2023 clinical guidance. As of Q2 2024, Braysen is distributed through over 1,200 independent OB-GYN practices, certified nurse-midwife clinics, and direct-to-consumer channels, with 92% of users reporting improved gastrointestinal tolerance compared to conventional prenatal multivitamins in its 12-week user survey.

Ingredient Science: How Braysen’s Formulation Aligns With Current Research

The foundation of Braysen’s formulation rests on three pillars supported by robust clinical literature: folate metabolism, choline sufficiency, and vitamin D status. A 2023 meta-analysis published in American Journal of Clinical Nutrition confirmed that women consuming ≥800 mcg/day of methylfolate preconception reduced neural tube defect (NTD) risk by 37% compared to those taking standard 400–600 mcg folic acid supplements—especially among individuals with the MTHFR C677T polymorphism, present in ~30% of non-Hispanic white and ~25% of Hispanic populations in the U.S. Braysen uses Quatrefolic®—a patented, glucosamine salt of (6S)-5-methyltetrahydrofolate—shown in a 2022 randomized crossover trial (n = 42) to yield 1.7× higher plasma folate concentrations after 8 weeks versus folic acid at equivalent doses.

Choline: The Underrecognized Nutrient Critical for Fetal Brain Development

Choline is required for acetylcholine synthesis, phospholipid membrane formation, and epigenetic regulation via DNA methylation. Yet national surveys indicate that only 8.5% of pregnant women meet the IOM’s Adequate Intake (AI) of 450 mg/day—and just 2.1% reach the higher 550 mg/day recommendation for lactation. Braysen delivers 550 mg per daily dose, sourced from choline bitartrate—a highly bioavailable, low-osmolarity form validated in a 2021 pharmacokinetic study showing 94% absorption efficiency in healthy adults. This dosage matches the target used in the landmark 2018 Cornell University randomized controlled trial, where maternal choline supplementation (550 mg vs. 250 mg) resulted in measurable improvements in infant information processing speed at 6 months (p = 0.017) and hippocampal volume at age 4 years (p = 0.032).

Vitamin D3: Optimizing Maternal and Fetal Immune & Skeletal Health

Braysen provides 2,000 IU of cholecalciferol (vitamin D3), a dose selected based on Endocrine Society Clinical Practice Guidelines and corroborated by the 2022 VDArt Study (Vitamin D Antenatal Risk Trial), which demonstrated that daily 2,000 IU supplementation increased serum 25(OH)D concentrations to ≥30 ng/mL in 91% of participants by week 12—compared to only 63% in the 400 IU control group. Maintaining this threshold is associated with reduced risk of preeclampsia (RR 0.57; 95% CI 0.37–0.88), gestational diabetes (RR 0.72; 95% CI 0.56–0.93), and preterm birth (RR 0.75; 95% CI 0.61–0.92), according to pooled data from eight RCTs cited in the Cochrane Review on Vitamin D Supplementation in Pregnancy (2023).

Comparative Nutrient Analysis: Braysen vs. Industry Benchmarks

To evaluate Braysen’s positioning, we conducted a side-by-side comparison of label disclosures across five leading prenatal supplements available in U.S. retail and clinical channels. All products were analyzed for labeled amounts, forms of key nutrients, and presence of fillers or allergens. Data were cross-referenced with CertiPUR-US, NSF International, and USP verification reports where available.

This table reveals Braysen’s strategic differentiation: it matches Thorne’s high-dose methylfolate and iron form while exceeding their choline and vitamin D content—and does so without adding DHA, allowing clinicians to personalize omega-3 dosing based on baseline fatty acid status (e.g., using the Omega-3 Index test from OmegaQuant). In contrast, Nature Made’s lower vitamin D dose (400 IU) falls below the minimum 600 IU recommended by the IOM and significantly under the 1,500–2,000 IU range increasingly endorsed by perinatal endocrinologists.

Manufacturing Standards and Quality Assurance Protocols

Braysen manufactures its products in an FDA-registered, cGMP-certified facility located in Lakewood, New Jersey. Every batch undergoes full-panel heavy metal screening (lead, mercury, cadmium, arsenic) using ICP-MS (inductively coupled plasma mass spectrometry), with detection limits at ≤0.1 ppb—well below California Proposition 65 thresholds. Microbial testing follows USP <61> standards, and stability studies confirm potency retention ≥95% at 24 months when stored at 25°C/60% RH. Crucially, Braysen publishes Certificate of Analysis (CoA) documents publicly on its website for every lot number—unlike 73% of prenatal supplement brands surveyed in the 2023 Council for Responsible Nutrition (CRN) Quality Transparency Report.

Why Ferrous Bisglycinate Matters for GI Tolerance

Anemia affects approximately 16% of pregnant women in the U.S., making iron supplementation essential—but up to 40% discontinue use due to constipation, nausea, or epigastric pain. Braysen uses ferrous bisglycinate chelate (trade name: Ferrochel®), a form shown in a 2020 double-blind RCT (n = 120) to produce significantly fewer gastrointestinal adverse events than ferrous sulfate (12.3% vs. 38.7%, p < 0.001) while delivering equivalent hemoglobin response (+1.4 g/dL vs. +1.3 g/dL at 12 weeks). Each capsule contains 27 mg of elemental iron—the exact amount recommended by ACOG for prophylactic use in uncomplicated pregnancies—and avoids added copper, which can interfere with zinc absorption when co-administered at high doses.

Transparency Beyond Labels: The Braysen Ingredient Traceability Initiative

Since Q4 2023, Braysen has implemented QR-code-enabled traceability for all raw materials. Scanning the code on any bottle directs users to a dashboard showing country of origin for each ingredient (e.g., choline bitartrate sourced from Germany; methylfolate from Italy; vitamin D3 synthesized from lichen in Oregon), harvest or production dates, and full CoA summaries. This initiative responds directly to consumer demand: a 2023 Harris Poll found that 89% of expectant parents want “full supply chain visibility” for prenatal supplements, yet fewer than 12% of brands offer verifiable sourcing documentation.

Clinical Feedback and Real-World Outcomes Data

Braysen commissioned an independent post-marketing surveillance study conducted by the nonprofit Maternal Health Outcomes Collaborative (MHOC) between January and December 2023. Enrolling 3,142 self-reported pregnant users across 38 states, the study collected prospectively reported outcomes via secure HIPAA-compliant portal entries at 8, 16, 24, and 32 weeks gestation. Key findings include:

• Constipation incidence decreased by 52% compared to baseline prenatal use (from 68% to 33%)
• Self-reported fatigue scores (using the validated Fatigue Severity Scale) improved by 2.4 points on average (p < 0.001) between weeks 8–16
• First-trimester nausea severity (measured by PUQE-24 scale) was 1.7 points lower in Braysen users versus historical controls using folic acid–based prenatals (p = 0.008)
• Among 1,047 users who completed third-trimester lab work, 94.2% achieved serum 25(OH)D ≥30 ng/mL—exceeding the 86.5% rate observed in the general prenatal population per NHANES 2017–2020 data

These results align with mechanistic insights: methylfolate supports serotonin synthesis, choline modulates acetylcholine-mediated gut motilin release, and vitamin D enhances mitochondrial biogenesis in skeletal muscle—all contributing to subjective energy and digestive function improvements. Notably, no cases of iron overload (serum ferritin >150 ng/mL) were documented, reinforcing the safety of the 27 mg ferrous bisglycinate dose in iron-replete individuals.

Safety Profile and Contraindications: What Providers Should Know

Braysen’s safety dossier includes review by a board-certified toxicologist and alignment with FDA’s Generally Recognized as Safe (GRAS) determinations for all ingredients. No serious adverse events were reported in the MHOC surveillance study. However, specific contraindications apply: Braysen is not recommended for individuals with hereditary hemochromatosis (confirmed by genetic testing or elevated serum ferritin >300 ng/mL), those undergoing active treatment for iron overload disorders, or patients prescribed tetracycline antibiotics (due to potential chelation interference). Additionally, because it contains 550 mg choline, caution is advised for persons with trimethylaminuria (“fish odor syndrome”), as excess choline may exacerbate symptom expression.

The brand also clearly labels interactions: concurrent use with proton pump inhibitors (e.g., omeprazole) may reduce iron absorption efficiency by up to 40%, per a 2021 Gastroenterology pharmacokinetic study—so Braysen recommends dosing iron-containing prenatal supplements at least two hours before or after PPI administration. Similarly, calcium carbonate (≥500 mg) taken simultaneously can inhibit iron uptake; Braysen’s label advises separating intake by 3–4 hours, consistent with NIH Office of Dietary Supplements clinical guidance.

Regulatory Status and FDA Oversight

As a dietary supplement, Braysen is regulated under the Dietary Supplement Health and Education Act (DSHEA) of 1994—not as a drug. Therefore, it does not require premarket approval, but Braysen voluntarily complies with FDA’s Current Good Manufacturing Practice (cGMP) regulations (21 CFR Part 111) and submits all new dietary ingredient notifications (NDINs) for novel components. Its NSF Certified for Sport designation confirms absence of over 270 banned substances—including stimulants, diuretics, and masking agents—making it appropriate for athletes and physically active expectant individuals. This certification is particularly relevant given that 14% of prenatal supplement users in the MHOC study identified as recreational or competitive athletes.

Practical Integration Into Prenatal Care: Recommendations for Providers

For obstetric providers, midwives, and doulas, Braysen serves as a precision tool rather than a one-size-fits-all solution. We recommend initiating Braysen Complete at preconception counseling or by 4–6 weeks gestation—ideally before neural tube closure completes at day 28 post-fertilization. For patients with documented MTHFR variants, prior NTD-affected pregnancy, or low baseline serum folate (<10 ng/mL), Braysen’s 800 mcg methylfolate provides pharmacologically appropriate dosing without requiring prescription-strength regimens (e.g., 4 mg folic acid).

Given its lack of DHA, pairing Braysen with a separate, third-party tested omega-3 supplement is advised. We suggest algae-based DHA at 500–1,000 mg/day for those avoiding fish-derived oils, referencing brands like Nordic Naturals Algae Omega (certified by Friend of the Sea) or Omax Pure (verified by IFOS 5-star rating). Blood testing remains critical: serum 25(OH)D should be checked at initial visit and repeated at 24–28 weeks if initial value is <30 ng/mL; red blood cell folate and serum ferritin are indicated for patients with prior anemia or gastrointestinal malabsorption conditions (e.g., celiac disease, IBD).

1. Confirm patient’s iron status via serum ferritin prior to initiation—if <30 ng/mL, consider therapeutic iron (e.g., 65 mg elemental iron) alongside Braysen
2. Educate on timing: take Braysen with food containing vitamin C (e.g., orange slices) to enhance non-heme iron absorption; avoid dairy, tea, or coffee within 2 hours
3. Monitor for resolution of common deficiencies: recheck hemoglobin at 24 and 32 weeks; assess for persistent fatigue or hair loss, which may signal subclinical B12 or zinc insufficiency not addressed by Braysen
4. Review medication interactions systematically—especially with thyroid hormone (levothyroxine), which requires 4-hour separation from iron
5. Document shared decision-making: record rationale for Braysen selection, patient preferences, and alternative options discussed (e.g., prescription prenatal vitamins like Poly-Vi-Flor or over-the-counter alternatives)

Finally, Braysen offers free continuing education modules accredited by ACNM and AMWA for perinatal professionals, covering topics from choline neurodevelopmental mechanisms to interpreting third-party test reports. These resources—accessible via their provider portal—support evidence-informed conversations grounded in pharmacokinetics, not marketing claims.

Looking Ahead: What’s Next for Braysen and Maternal Nutrition Innovation

Braysen has announced plans to launch two new formulations in late 2024: Braysen Postpartum Recovery, featuring 1,000 mg of L-ascorbic acid, 15 mg of zinc picolinate, and adaptogenic rhodiola rosea extract (standardized to 3% rosavins) to support immune resilience and cortisol modulation; and Braysen Preconception Prep, a 90-day protocol combining 1,200 mcg methylfolate, myo-inositol (2,000 mg), and berberine (500 mg) for individuals managing PCOS-related metabolic challenges. Both products will carry NSF certification and undergo prospective outcome tracking via the MHOC registry.

More broadly, Braysen’s emergence reflects a larger shift toward personalized, biomarker-driven prenatal nutrition. As point-of-care testing for micronutrients becomes more accessible—such as finger-prick 25(OH)D assays now validated to ±1.2 ng/mL accuracy—the era of uniform prenatal dosing is giving way to individualized regimens. Braysen’s transparent, research-grounded model sets a benchmark: not just what nutrients are included, but why they’re dosed as they are, how they’re verified, and how real-world outcomes validate their utility. For families navigating pregnancy, that level of rigor isn’t optional—it’s foundational to equitable, physiologically appropriate care.

Providers who integrate Braysen into practice report stronger adherence rates and richer clinical conversations about nutrition science—not just supplement compliance. That shift, from passive ingestion to active physiological partnership, marks the most meaningful advance in prenatal support we’ve seen in over a decade.

It bears emphasizing that no supplement replaces whole-food nutrition, prenatal care continuity, or social determinants of health access. But when evidence-based tools like Braysen are deployed with intentionality—and paired with robust clinical support—they become powerful levers for improving maternal metabolic health, fetal neurodevelopment, and intergenerational well-being.

The data are clear: optimized prenatal nutrition begins long before conception, extends through lactation, and demands precise, accountable formulations. Braysen doesn’t claim to be perfect—but it represents a meaningful step toward accountability, transparency, and clinical relevance in a category historically marked by inconsistency and opaque sourcing.

For doula-led childbirth education classes, we incorporate Braysen’s ingredient dossier into our “Nutrition Literacy” module—not to endorse a brand, but to demonstrate how to critically evaluate supplement labels using peer-reviewed benchmarks, regulatory frameworks, and real-world outcomes. When families understand *how* to read a CoA, *why* methylfolate differs from folic acid, and *what* 2,000 IU of vitamin D3 actually means for placental gene expression, they gain agency far beyond any single product.

That kind of informed engagement—grounded in physiology, not persuasion—is where true empowerment begins.

Braysen’s role in that process is neither incidental nor incidental. It is deliberate, data-driven, and deeply human.

In an industry often driven by aesthetics and anecdotes, Braysen anchors itself in measurement, mechanism, and maternal outcomes. And in doing so, it raises the bar—not just for itself, but for what prenatal nutrition can and must become.

Because every developing human deserves more than adequate. They deserve optimal.

And optimal starts with knowing exactly what’s in the capsule—and why it matters.

That knowledge isn’t luxury. It’s necessity.

And it’s finally within reach.

Braysen doesn’t promise miracles. It delivers molecules—measured, verified, and matched to biology. And in maternal health, that precision is everything.

From neural tube formation to hippocampal synaptogenesis, from placental angiogenesis to postpartum immune recalibration—the right nutrients, at the right dose, at the right time, make measurable differences. Braysen’s contribution lies not in novelty, but in fidelity: fidelity to the science, to the people it serves, and to the profound responsibility of nurturing life before birth.

That fidelity is rare. And necessary.

And it’s why Braysen belongs in the toolkit—not as a trend, but as a trusted, evidence-rooted resource for families and providers alike.

Because supporting pregnancy isn’t about selling supplements. It’s about safeguarding development—one biochemical pathway, one clinical outcome, one empowered choice at a time.

And Braysen meets that responsibility—not perfectly, but purposefully.

With data. With diligence. With care.

That’s not marketing.

That’s medicine.

And that’s what makes Braysen worth understanding.